VTGN — Vistagen Therapeutics Balance Sheet
0.000.00%
- $85.70m
- $5.22m
- $0.49m
Annual balance sheet for Vistagen Therapeutics, fiscal year end - March 31st, USD millions except per share, conversion factor applied.
2021 March 31st | 2022 March 31st | 2023 March 31st | 2024 March 31st | 2025 March 31st | |
---|---|---|---|---|---|
Period Length: | — | — | — | — | — |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Cash and Equivalents | |||||
Short Term Investments | |||||
Cash and Short Term Investments | 103 | 68.1 | 16.6 | 119 | 80.5 |
Net Total Receivables | 0.041 | 0.338 | 0.275 | — | — |
Prepaid Expenses | |||||
Total Other Current Assets | |||||
Total Current Assets | 104 | 71 | 17.5 | 121 | 82.1 |
Gross Property, Plant And Equipment | |||||
Accumulated Depreciation | |||||
Net Property, Plant And Equipment | 3.59 | 3.08 | 2.77 | 2.25 | 1.81 |
Other Long Term Assets | |||||
Total Assets | 108 | 74.6 | 21.1 | 124 | 84.3 |
Accounts Payable | |||||
Accrued Expenses | |||||
Notes Payable / Short Term Debt | |||||
Current Portion of Long Term Debt / Capital Leases | |||||
Total Other Current Liabilities | |||||
Total Current Liabilities | 4.19 | 5.77 | 4.57 | 5.12 | 12.6 |
Capital Lease Obligations | |||||
Total Long Term Debt | |||||
Total Debt | |||||
Total Other Liabilities | |||||
Total Liabilities | 16.3 | 9.93 | 9.01 | 9.37 | 14 |
Non Redeemable Preferred Stock | |||||
Common Stock | |||||
Additional Paid In Capital | |||||
Retained Earnings (Accumulated Deficit) | |||||
Treasury Stock | |||||
Other Equity | |||||
Total Equity | 92 | 64.7 | 12.1 | 114 | 70.4 |
Total Liabilities & Shareholders' Equity | 108 | 74.6 | 21.1 | 124 | 84.3 |
Total Common Shares Outstanding | |||||
Total Preferred Shares Outstanding |